7499-73-2

Usage

Uses

Used in Organic Synthesis:
N-(4-bromo-2-nitronaphthalen-1-yl)acetamide is used as a reagent in organic synthesis for the creation of various chemical compounds. Its unique structure and properties make it a valuable component in the synthesis of new molecules with specific functions and applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-(4-bromo-2-nitronaphthalen-1-yl)acetamide is used as a building block for the development of new drugs. Its chemical properties allow it to be incorporated into the molecular structures of potential therapeutic agents, contributing to their efficacy and selectivity.
Used in Agrochemical Industry:
N-(4-bromo-2-nitronaphthalen-1-yl)acetamide also finds application in the agrochemical industry, where it is used as a component in the synthesis of pesticides and other agricultural chemicals. Its presence in these compounds can enhance their effectiveness in controlling pests and diseases, thereby improving crop yields and quality.

Upstream product

• 2437-30-1 N-(2-nitronaphthalen-1-yl)acetamide 
• 24402-72-0 N-(4-nitronaphthalen-1-yl)acetamide 
• 91394-66-0 1-(acetylamino)-4-bromonaphthalene 
• 861798-43-8 N-(4-bromo-5,8-dihydro-[1]naphthyl)-acetamide 
• 64-19-7 acetic acid 
• 7697-37-2 nitric acid 
• 32666-56-1 1-amino-5,8-dihydronaphthalene 
• 7664-93-9 sulfuric acid 
• 575-36-0 1-acetamidonaphthalene 
• 2298-07-9 4-Bromo-1-naphthylamine 
• 108-24-7 acetic anhydride 
• 861294-59-9 N-(4,6,7-tribromo-5,6,7,8-tetrahydro-[1]naphthyl)-acetamide 

Downstream Products

• 62148-28-1 5-bromo-2-methyl-1⁽³⁾H-naphtho[1,2-d]imidazole 
• 90767-01-4 4-bromo-2-nitro-1-naphthylamine 
• 905302-18-3 4-bromo-2-nitro-[1]naphthol 
• 33670-68-7 4-bromo-1-diazonio-naphthalen-2-olate 
• 759398-90-8 4-bromo-1-chloro-[2]naphthylamine 
• 51670-69-0 N-(4-bromo-1-chloro-[2]naphthyl)-acetamide 
• 52289-50-6 1,4-dibromo-2-nitro-naphthalene 
• 858024-98-3 N,N'-(4-bromo-naphthalene-1,2-diyl)-bis-acetamide 
• 7499-65-2 4-bromo-2-nitronaphthalene 
• 74924-94-0 4-bromonaphthalene-2-amine 
• 1578179-15-3 2-(4-iodonaphthalen-2-ylamino)-5-nitrobenzoic acid 
• 1071083-21-0 4-bromo-1-iodo-2-nitronaphthalene 
• 102170-75-2 4,4'-dibromo-2,2'-dinitro-[1,1']binaphthyl 

Relevant academic research and scientific papers

KRAS G12D INHIBITORS

The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

METHODS AND FORMULATIONS TO TREAT MITOCHONDRIAL DYSFUNCTION

Methods of treatment and pharmaceutical formulations configured to treat primary and secondary mitochondrial dysfunction are provided. The methods and treatments use an agonist of AMPK. The agonist activates AMPK to activate ATP-producing pathways and inhibiting ATP-consuming pathways, thus allowing for the alleviation of symptoms associated with mitochondrial dysfunctions.

Novel compound and organic light emitting device comprising the same

The present invention provides: a novel compound each comprising an amino group at both ends of a molecule; and an organic light emitting device comprising the same. When the compound of chemical formula 1 of the present invention is applied to the organic light emitting device, it is possible to improve efficiency, lower driving voltage, and improve lifespan characteristics of the organic light emitting device.COPYRIGHT KIPO 2020

Novel compound and organic light emitting device comprising the same

The present invention provides a novel compound and an organic light emitting device having same. The present invention also provides the organic light emitting device comprising: a first electrode; a second electrode facing the first electrode; and one or more organic substances provided between the first electrode and the second electrode.COPYRIGHT KIPO 2019

Novel compound and organic light emitting device comprising the same

The present invention provides a novel compound containing amino groups at both ends of a molecule and an organic light emitting device having the novel compound. The present invention also provides the organic light emitting device comprising: a first electrode; a second electrode facing the first electrode; and at least one organic material layer provided between the first electrode and the second electrode.COPYRIGHT KIPO 2019

Monna, a potent and selective blocker for transmembrane protein with unknown function 16/anoctamin-1

Transmembrane protein with unknown function 16/anoctamin-1 (ANO1) is a protein widely expressed in mammalian tissues, and it has the properties of the classic calcium-activated chloride channel (CaCC). This protein has been implicated in numerous major physiological functions. However, the lack of effective and selective blockers has hindered a detailed study of the physiological functions of this channel. In this study, we have developed a potent and selective blocker for endogenous ANO1 in Xenopus laevis oocytes (xANO1) using a drug screening method we previously established (Oh et al., 2008). We have synthesized a number of anthranilic acid derivatives and have determined the correlation between biological activity and the nature and position of substituents in these derived compounds. A structure-activity relationship revealed novel chemical classes of xANO1 blockers. The derivatives contain a-NO2 group on position 5 of a naphthyl group-substituted anthranilic acid, and they fully blocked xANO1 chloride currents with an IC 5050 of 0.08 μM for xANO1. Selectivity tests revealed that other chloride channels such as bestrophin-1, chloride channel protein 2, and cystic fibrosis transmembrane conductance regulator were not appreciably blocked by 10～30 μM MONNA. The potent and selective blockers for ANO1 identified here should permit pharmacological dissection of ANO1/CaCC function and serve as potential candidates for drug therapy of related diseases such as hypertension, cystic fibrosis, bronchitis, asthma, and hyperalgesia.

Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents

The present invention relates to ion channel modulating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as modulators of SKCa, IKCa and BKCa channels. In further aspects, the present invention relates to the use of these SK/IK/BK channel modulating agents for the manufacture of medicaments, and pharmaceutical compositions comprising the SK/IK/BK channel modulating agents. The SK/IK/BK channel modulating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK/BK channels.